innovation for industry
Article | Micro-nanoelectronics
A unique interface between patients and the medical industry
Hub4aim has an unique proposal to manage the preindustrial
phase from the proof of concept to regulatory marking.
Clinatec has been trying to effectively determine the best location in the brain for its WIMAGINE® implant, which measures the brain activity of tetraplegic patients.
The CEA, Grenoble Alpes University Hospital, Grenoble Alpes University and Boston Scientific Corporation, a leading company in medical devices, have started on the Near Infra Red (NIR) project clinical trial in March 2021.
From January 11 to 14, 2021, the CEA will participate in the Consumer Electronic Show (CES) for the 7th consecutive year. For this 100% digital version, the CEA is supporting 3 startups spun off from its laboratories that have developed technological solutions in response to three major societal challenges: the energy transition, the digital transition and the medicine of the future.
Iprasense has just released its third product, one that leverages a lensless imaging technology protected by around a dozen patents. The company’s latest offering is particularly well-suited for high-throughput cellular screening in drug discovery.
The Epicool project is investigating the use of optics to cool epileptogenic areas in the brains of epilepsy patients resistant to other treatments. A prototype implantable device is currently being developed and will be miniaturized before animal testing begins.
Nano-biotechnology PlatformClinatec Platform
Connected Health ＆ WellnessAgriculture, Food Industry ＆ Environment
Smart Medical Technologies
See all demos
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.